Alpha-1-Antitrypsin, Serum

Alpha-1-Antitrypsin is an acute phase reactant. This means that it will be elevated in acute and chronic inflammatory conditions, infections, and with some cancers. Increased levels of Alpha-1-Antitrypsin may also be seen with oral contraceptive use, pregnancy, and stress. These temporary or chronic Alpha-1-Antitrypsin increases may cause levels to appear normal in people with mild to moderate Alpha-1-Antitrypsin deficiency.

If your results show a lower than normal amount of Alpha-1 antitrypsin, it probably means you have one or two mutated Alpha-1 antitrypsin genes. The lower the level, the more likely it is you have two mutated genes and Alpha-1 antitrypsin deficiency.

- Alpha-1 antitrypsin deficiency is caused by an inherited gene mutation.

- Infants may develop jaundice and liver damage.

- Cirrhosis can develop during childhood.

- Adults commonly develop emphysema, with shortness of breath, wheezing, and coughing, and some adults develop cirrhosis.

- Tests that measure the amount of the enzyme in the blood and that detect the gene mutations are used for diagnosis.

- People with emphysema take drugs to improve breathing and sometimes receive infusions of alpha-1 antitrypsin by vein.

- Some people need lung or liver transplants.

Less than 125 mg/dL:

If clinically indicated, patients with serum levels less than 125 mg/dL should be proteotyped in order to identify heterozygous individuals. Heterozygotes do not appear to be at increased risk for early emphysema.

Less than 70 mg/dL:

People with serum levels less than 70 mg/dL may have a homozygous deficiency and are at risk for early lung disease. Alpha-1-antitrypsin proteotyping should be done to confirm the presence of homozygous deficiency alleles. 

What does homozygous and heterozygotes mean?

Alternative forms of a given gene are called alleles, and they can be dominant or recessive. When an individual has two of the same allele, whether dominant or recessive, they are homozygous. Heterozygous means having one each of two different alleles.

Low alpha-1-antitrypsin levels may result from liver disease, and alpha-1-antitrypsin proteotyping should be done to confirm deficiency disease.

Potential symptoms:

Symptoms may first appear during infancy, childhood, or adulthood. About 10 to 20% of affected people have symptoms during infancy. Affected infants develop yellowing of the skin and the whites of the eyes (jaundice) and an enlarged liver during the first week of life. Jaundice disappears at about age 2 to 4 months. However, about 20% of these infants later develop cirrhosis, and some die before reaching adulthood.

Adults commonly develop emphysema, with progressively increasing shortness of breath, difficulty breathing, coughing, and wheezing. Emphysema rarely develops before age 25. It develops earlier and is more severe in smokers than in nonsmokers. The severity of symptoms also varies depending on the form of the deficiency, other disorders people have, environmental exposure to lung irritants, and other factors. If people have never smoked, their symptoms tend to be moderate, and most have a normal life expectancy.

Even if they did not have liver problems during infancy, about 10% of adults develop cirrhosis, which may eventually lead to liver cancer.

People with panniculitis have painful, tender bumps or discolored patches on the lower abdomen, buttocks, and thighs. The bumps may feel hard to the touch.

Potential treatment:

Emphysema: People who smoke are advised to stop. Bronchodilators, drugs that relax the muscles around the small airways and thus widen the airways, such as albuterol may help ease breathing and relieve cough. Lung infections that develop are treated promptly.

Alpha-1 antitrypsin may be given by vein to replace the deficient enzyme. It is collected from a group of donors and screened for bloodborne disorders. Thus, it is expensive and is most beneficial to people who have only moderate symptoms due to emphysema and do not smoke. This treatment is thought to prevent further damage but does not reverse damage already done.

If people are younger than 60 and have severe symptoms, lung transplantation may be done. A few medical centers sometimes do transplantations in highly selected people as old as 70. A few medical centers also sometimes do lung volume reduction surgery.

Liver damage: Taking alpha-1 antitrypsin does not treat or prevent liver damage because liver damage is caused by production of an abnormal enzyme, not by enzyme deficiency. If the liver is severely damaged, liver transplantation may be done. The transplanted liver does not become damaged because the alpha-1 antitrypsin it produces is normal and thus does not accumulate in the liver.

Panniculitis: Doctors may give corticosteroids, antimalarial drugs, or certain antibiotics (tetracyclines) to relieve inflammation. But whether these drugs are effective is unclear.

Alpha-1 antitrypsin deficiency is a hereditary disorder in which a lack or low level of the enzyme alpha-1 antitrypsin damages the lungs and liver.